• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

自体造血干细胞移植后伴多发性骨髓瘤相关进展性肾衰竭患者的长期预后。

Long-term outcome of patients with multiple [corrected] myeloma-related advanced renal failure following auto-SCT.

机构信息

Department of Hematology, Galway University Hospital, Galway, Ireland.

出版信息

Bone Marrow Transplant. 2013 Nov;48(12):1543-7. doi: 10.1038/bmt.2013.109. Epub 2013 Aug 5.

DOI:10.1038/bmt.2013.109
PMID:23912663
Abstract

Renal failure commonly complicates multiple myeloma (MM) and is associated with reduced survival. It is not clear whether auto-SCT results in improved renal function or attainment of independence from dialysis in patients with advanced renal impairment due to MM. We conducted a retrospective cohort study of all patients who underwent auto-SCT for MM complicated by advanced renal failure at our institution over a 10-year period (2000-2010). We aimed to assess the association between auto-SCT and renal outcome in patients with serum creatinine (SCr) over 3 mg/dL, attributable to MM, including those who were dialysis dependent. Thirty patients (2.8% of all auto-SCT patients) met inclusion criteria. Fourteen of 15 patients who were dialysis dependent before auto-SCT remained dialysis dependent in the long term despite hematological response (HR). Of the remaining 15 patients with SCr >3 mg/dL, an improvement in glomerular filtration rate (GFR) from 15 to 19.4 mL/min/1.73 m(2) was noted post auto-SCT (P=0.035); however, neither HR post auto-SCT or pre-existing renal function were independently associated with renal outcome. Auto-SCT was not associated with independence from dialysis in patients with renal failure due to MM at our institution. Although auto-SCT was associated with an improvement in GFR in patients with SCr >3 mg/dL, this improvement was not related to HR.

摘要

肾衰竭常并发多发性骨髓瘤(MM),并与降低生存率相关。目前尚不清楚自体造血干细胞移植(auto-SCT)是否会改善肾功能,或是否能使因 MM 导致的严重肾功能损害患者免于透析。我们对本机构 10 年内(2000-2010 年)所有因严重肾衰竭而行自体造血干细胞移植治疗的 MM 患者进行了回顾性队列研究。我们旨在评估自体造血干细胞移植治疗血清肌酐(SCr)>3mg/dL(归因于 MM,包括依赖透析患者)患者的肾功能结局。符合纳入标准的患者共 30 例(占所有自体造血干细胞移植患者的 2.8%)。15 例在自体造血干细胞移植前依赖透析的患者中,尽管有血液学反应(HR),但在长期内仍依赖透析。在剩余的 15 例 SCr>3mg/dL 的患者中,自体造血干细胞移植后肾小球滤过率(GFR)从 15ml/min/1.73m2 提高到 19.4ml/min/1.73m2(P=0.035);然而,HR 或移植前肾功能均与移植后的肾功能结局无相关性。本机构的自体造血干细胞移植治疗 MM 所致肾衰竭患者,并未使其免于透析。尽管自体造血干细胞移植治疗与 SCr>3mg/dL 患者的 GFR 提高有关,但这种改善与 HR 无关。

相似文献

1
Long-term outcome of patients with multiple [corrected] myeloma-related advanced renal failure following auto-SCT.自体造血干细胞移植后伴多发性骨髓瘤相关进展性肾衰竭患者的长期预后。
Bone Marrow Transplant. 2013 Nov;48(12):1543-7. doi: 10.1038/bmt.2013.109. Epub 2013 Aug 5.
2
Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma.异基因造血干细胞移植治疗多发性骨髓瘤患者的强化预处理与非强化预处理的长期疗效比较
Am J Hematol. 2013 May;88(5):370-4. doi: 10.1002/ajh.23412. Epub 2013 Mar 5.
3
Results of autologous stem cell transplant in multiple myeloma patients with renal failure.肾衰竭多发性骨髓瘤患者自体干细胞移植的结果
Br J Haematol. 2001 Sep;114(4):822-9. doi: 10.1046/j.1365-2141.2001.03033.x.
4
Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method.采用简化方法的难治性或复发性淋巴瘤患者门诊接受低强度异基因干细胞移植与自体干细胞移植的比较。
Ann Hematol. 2010 Oct;89(10):1045-52. doi: 10.1007/s00277-010-0986-1. Epub 2010 May 21.
5
Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up.自体/减低强度预处理异基因干细胞移植与骨髓瘤自体移植的比较:长期随访。
J Clin Oncol. 2011 Aug 1;29(22):3016-22. doi: 10.1200/JCO.2010.32.7312. Epub 2011 Jul 5.
6
High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease.单克隆Ig沉积病患者的大剂量美法仑与自体造血干细胞移植
Bone Marrow Transplant. 2008 Sep;42(6):405-12. doi: 10.1038/bmt.2008.179. Epub 2008 Jun 23.
7
Matched-pair analysis to compare the outcomes of a second salvage auto-SCT to systemic chemotherapy alone in patients with multiple myeloma who relapsed after front-line auto-SCT.对一线自体外周血干细胞移植(auto-SCT)后复发的多发性骨髓瘤患者,采用配对分析比较挽救性自体外周血干细胞移植(second salvage auto-SCT)与单纯全身化疗的疗效。
Bone Marrow Transplant. 2013 Mar;48(3):425-32. doi: 10.1038/bmt.2012.164. Epub 2012 Sep 3.
8
Long-term outcome of autologous stem cell transplantation in light chain deposition disease.轻链沉积病自体干细胞移植的长期预后
Nephrol Dial Transplant. 2008 Jun;23(6):2052-7. doi: 10.1093/ndt/gfm918. Epub 2008 Jan 4.
9
Treatment of multiple myeloma.多发性骨髓瘤的治疗。
Haematologica. 1999 Jan;84(1):36-58.
10
[Autologous haematopoietic stem cell transplantation in patients with multiple myeloma complicated by dialysis-dependent renal failure].[自体造血干细胞移植治疗合并依赖透析的肾衰竭的多发性骨髓瘤患者]
Ter Arkh. 2020 Sep 1;92(7):70-76. doi: 10.26442/00403660.2020.07.000777.

引用本文的文献

1
The Role of Chloride Channels in the Multidrug Resistance.氯离子通道在多药耐药中的作用。
Membranes (Basel). 2021 Dec 28;12(1):38. doi: 10.3390/membranes12010038.
2
Induction Therapy with Novel Agents and Autologous Stem Cell Transplant Overcomes the Adverse Impact of Renal Impairment in Multiple Myeloma.新型药物诱导疗法与自体干细胞移植可克服肾功能损害对多发性骨髓瘤的不利影响。
Clin Hematol Int. 2019 Aug 23;1(4):205-219. doi: 10.2991/chi.d.190805.003. eCollection 2019 Dec.
3
Current diagnosis, risk stratification and treatment paradigms in newly diagnosed multiple myeloma.
新诊断多发性骨髓瘤的当前诊断、风险分层及治疗模式
Cancer Treat Res Commun. 2021;29:100444. doi: 10.1016/j.ctarc.2021.100444. Epub 2021 Aug 4.
4
Acute Kidney Injury in Patients Receiving Systemic Treatment for Cancer: A Population-Based Cohort Study.癌症患者接受全身治疗后的急性肾损伤:基于人群的队列研究。
J Natl Cancer Inst. 2019 Jul 1;111(7):727-736. doi: 10.1093/jnci/djy167.
5
Measured GFR in Routine Clinical Practice-The Promise of Dried Blood Spots.在常规临床实践中测量肾小球滤过率 - 干血斑的前景。
Adv Chronic Kidney Dis. 2018 Jan;25(1):76-83. doi: 10.1053/j.ackd.2017.09.003.
6
ClC5 Decreases the Sensitivity of Multiple Myeloma Cells to Bortezomib via Promoting Prosurvival Autophagy.氯离子通道 5 通过促进生存自噬降低多发性骨髓瘤细胞对硼替佐米的敏感性。
Oncol Res. 2018 Apr 10;26(3):421-429. doi: 10.3727/096504017X15049221237147. Epub 2017 Sep 11.
7
Current Trends of Renal Impairment in Multiple Myeloma.多发性骨髓瘤的肾功能损害的当前趋势。
Kidney Dis (Basel). 2016 Mar;1(4):241-57. doi: 10.1159/000442511. Epub 2016 Feb 3.
8
Aloperine executes antitumor effects against multiple myeloma through dual apoptotic mechanisms.刺芒柄花素通过双重凋亡机制对多发性骨髓瘤发挥抗肿瘤作用。
J Hematol Oncol. 2015 Mar 15;8:26. doi: 10.1186/s13045-015-0120-x.
9
Bortezomib improves outcome after SCT in multiple myeloma patients with end-stage renal failure.硼替佐米可改善终末期肾衰竭多发性骨髓瘤患者自体造血干细胞移植后的预后。
Bone Marrow Transplant. 2014 Nov;49(11):1371-5. doi: 10.1038/bmt.2014.165. Epub 2014 Aug 4.
10
How we manage autologous stem cell transplantation for patients with multiple myeloma.我们如何为多发性骨髓瘤患者管理自体干细胞移植。
Blood. 2014 Aug 7;124(6):882-90. doi: 10.1182/blood-2014-03-544759. Epub 2014 Jun 27.